KYMR vs. ADMA, RXRX, NVAX, BEAM, CGON, SANA, VCEL, FUSN, INBX, and IMCR
Should you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include ADMA Biologics (ADMA), Recursion Pharmaceuticals (RXRX), Novavax (NVAX), Beam Therapeutics (BEAM), CG Oncology (CGON), Sana Biotechnology (SANA), Vericel (VCEL), Fusion Pharmaceuticals (FUSN), Inhibrx (INBX), and Immunocore (IMCR). These companies are all part of the "biological products, except diagnostic" industry.
ADMA Biologics (NASDAQ:ADMA) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.
ADMA Biologics has a net margin of -1.29% compared to ADMA Biologics' net margin of -194.67%. Kymera Therapeutics' return on equity of 17.24% beat ADMA Biologics' return on equity.
In the previous week, Kymera Therapeutics had 6 more articles in the media than ADMA Biologics. MarketBeat recorded 10 mentions for Kymera Therapeutics and 4 mentions for ADMA Biologics. Kymera Therapeutics' average media sentiment score of 1.19 beat ADMA Biologics' score of 0.37 indicating that ADMA Biologics is being referred to more favorably in the media.
ADMA Biologics has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500.
ADMA Biologics received 365 more outperform votes than Kymera Therapeutics when rated by MarketBeat users. Likewise, 71.68% of users gave ADMA Biologics an outperform vote while only 48.19% of users gave Kymera Therapeutics an outperform vote.
ADMA Biologics currently has a consensus target price of $10.50, suggesting a potential upside of 8.92%. Kymera Therapeutics has a consensus target price of $42.70, suggesting a potential upside of 24.96%. Given ADMA Biologics' higher probable upside, analysts clearly believe Kymera Therapeutics is more favorable than ADMA Biologics.
75.7% of ADMA Biologics shares are owned by institutional investors. 3.7% of ADMA Biologics shares are owned by insiders. Comparatively, 15.8% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
ADMA Biologics has higher revenue and earnings than Kymera Therapeutics. ADMA Biologics is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
ADMA Biologics beats Kymera Therapeutics on 12 of the 19 factors compared between the two stocks.
Get Kymera Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kymera Therapeutics Competitors List
Related Companies and Tools
